TroVax: Phase II started

Oxford BioMedica said the Velindre Cancer Centre began the open-label, U.K. Phase II SKOPOS trial to evaluate TroVax every 3 weeks for 9 cycles plus pemetrexed and cisplatin in 26 patients. The trial ...